Diabetes drug may fight inflammation after stent procedure
NCT ID NCT07292909
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a diabetes drug, can reduce inflammation after a heart stent procedure. 100 patients with stable coronary artery disease will take either empagliflozin or a placebo for three days before their scheduled stent placement. Researchers will measure C-reactive protein (CRP) levels before and after the procedure to see if the drug lowers the inflammatory response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin
What this could lead to
If it works, this could show that empagliflozin reduces inflammation after stent placement, potentially improving recovery and outcomes for heart patients.
What could go wrong
This is a small, early-phase trial focused on a biomarker (CRP), not clinical outcomes. The anti-inflammatory effect may be modest or not translate to real-world benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hotel Dieu de France
RECRUITINGBeirut, Beirut, 00000, Lebanon
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••